TNA
RVNC

True North Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History

True North Advisors’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-21,720
Closed -$321K – 195
2020
Q1 		$321K Buy
+21,720
New +$449K 0.11% 93

Other funds holding RVNC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

True North Advisors's RVNC Position: Q2 2020 in Review

True North Advisors sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2020, closing a stake of 21,720 shares — an estimated $321K sold.

True North Advisors first reported a position in RVNC in Q1 2020 and held it in 1 quarter. The position peaked at $321K in Q1 2020. 144 funds tracked by Wall St. Rank hold RVNC as of Q2 2020.

  • True North Advisors reported no remaining Revance Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
  • True North Advisors sold 21,720 Revance Therapeutics, Inc. shares in Q2 2020, an estimated $321K.
  • True North Advisors first reported a position in Revance Therapeutics, Inc. in Q1 2020 and held it in 1 quarter.
  • True North Advisors's Revance Therapeutics, Inc. position peaked at $321K in Q1 2020.
  • 144 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2020.

Based on True North Advisors's 13F filing for Q2 2020, filed 20 May 2022.